293 related articles for article (PubMed ID: 35357463)
1. Dopaminergic medication normalizes aberrant cognitive control circuit signalling in Parkinson's disease.
Cai W; Young CB; Yuan R; Lee B; Ryman S; Kim J; Yang L; Henderson VW; Poston KL; Menon V
Brain; 2022 Nov; 145(11):4042-4055. PubMed ID: 35357463
[TBL] [Abstract][Full Text] [Related]
2. Dopamine controls Parkinson's tremor by inhibiting the cerebellar thalamus.
Dirkx MF; den Ouden HE; Aarts E; Timmer MH; Bloem BR; Toni I; Helmich RC
Brain; 2017 Mar; 140(3):721-734. PubMed ID: 28073788
[TBL] [Abstract][Full Text] [Related]
3. Functional segregation of basal ganglia pathways in Parkinson's disease.
Neumann WJ; Schroll H; de Almeida Marcelino AL; Horn A; Ewert S; Irmen F; Krause P; Schneider GH; Hamker F; Kühn AA
Brain; 2018 Sep; 141(9):2655-2669. PubMed ID: 30084974
[TBL] [Abstract][Full Text] [Related]
4. Dopamine depletion impairs gait automaticity by altering cortico-striatal and cerebellar processing in Parkinson's disease.
Gilat M; Bell PT; Ehgoetz Martens KA; Georgiades MJ; Hall JM; Walton CC; Lewis SJG; Shine JM
Neuroimage; 2017 May; 152():207-220. PubMed ID: 28263926
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic basis for impairments in functional connectivity across subdivisions of the striatum in Parkinson's disease.
Bell PT; Gilat M; O'Callaghan C; Copland DA; Frank MJ; Lewis SJ; Shine JM
Hum Brain Mapp; 2015 Apr; 36(4):1278-91. PubMed ID: 25425542
[TBL] [Abstract][Full Text] [Related]
6. Freezing of gait in Parkinson's disease is associated with functional decoupling between the cognitive control network and the basal ganglia.
Shine JM; Matar E; Ward PB; Frank MJ; Moustafa AA; Pearson M; Naismith SL; Lewis SJ
Brain; 2013 Dec; 136(Pt 12):3671-81. PubMed ID: 24142148
[TBL] [Abstract][Full Text] [Related]
7. Distinct alterations in Parkinson's medication-state and disease-state connectivity.
Ng B; Varoquaux G; Poline JB; Thirion B; Greicius MD; Poston KL
Neuroimage Clin; 2017; 16():575-585. PubMed ID: 28971008
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic modulation of motor network dynamics in Parkinson's disease.
Michely J; Volz LJ; Barbe MT; Hoffstaedter F; Viswanathan S; Timmermann L; Eickhoff SB; Fink GR; Grefkes C
Brain; 2015 Mar; 138(Pt 3):664-78. PubMed ID: 25567321
[TBL] [Abstract][Full Text] [Related]
9. Effects of levodopa on corticostriatal circuits supporting working memory in Parkinson's disease.
Simioni AC; Dagher A; Fellows LK
Cortex; 2017 Aug; 93():193-205. PubMed ID: 28675834
[TBL] [Abstract][Full Text] [Related]
10. Impulse control disorder in Parkinson's disease is associated with abnormal frontal value signalling.
Tichelaar JG; Sayalı C; Helmich RC; Cools R
Brain; 2023 Sep; 146(9):3676-3689. PubMed ID: 37192341
[TBL] [Abstract][Full Text] [Related]
11. Cognitive states influence dopamine-driven aberrant learning in Parkinson's disease.
Cavanagh JF; Mueller AA; Brown DR; Janowich JR; Story-Remer JH; Wegele A; Richardson SP
Cortex; 2017 May; 90():115-124. PubMed ID: 28384481
[TBL] [Abstract][Full Text] [Related]
12. Atomoxetine restores the response inhibition network in Parkinson's disease.
Rae CL; Nombela C; Rodríguez PV; Ye Z; Hughes LE; Jones PS; Ham T; Rittman T; Coyle-Gilchrist I; Regenthal R; Sahakian BJ; Barker RA; Robbins TW; Rowe JB
Brain; 2016 Aug; 139(Pt 8):2235-48. PubMed ID: 27343257
[TBL] [Abstract][Full Text] [Related]
13. The Iowa Gambling Task in Parkinson's disease: A meta-analysis on effects of disease and medication.
Evens R; Hoefler M; Biber K; Lueken U
Neuropsychologia; 2016 Oct; 91():163-172. PubMed ID: 27475264
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease.
Jahanshahi M; Jones CR; Zijlmans J; Katzenschlager R; Lee L; Quinn N; Frith CD; Lees AJ
Brain; 2010 Mar; 133(Pt 3):727-45. PubMed ID: 20305278
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.
Cools R; Stefanova E; Barker RA; Robbins TW; Owen AM
Brain; 2002 Mar; 125(Pt 3):584-94. PubMed ID: 11872615
[TBL] [Abstract][Full Text] [Related]
16. The impact of dopaminergic treatment over cognitive networks in Parkinson's disease: Stemming the tide?
Aracil-Bolaños I; Sampedro F; Pujol J; Soriano-Mas C; Gónzalez-de-Echávarri JM; Kulisevsky J; Pagonabarraga J
Hum Brain Mapp; 2021 Dec; 42(17):5736-5746. PubMed ID: 34510640
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic modulation of memory and affective processing in Parkinson depression.
Blonder LX; Slevin JT; Kryscio RJ; Martin CA; Andersen AH; Smith CD; Schmitt FA
Psychiatry Res; 2013 Nov; 210(1):146-9. PubMed ID: 23838419
[TBL] [Abstract][Full Text] [Related]
18. Dopamine restores cognitive motivation in Parkinson's disease.
McGuigan S; Zhou SH; Brosnan MB; Thyagarajan D; Bellgrove MA; Chong TT
Brain; 2019 Mar; 142(3):719-732. PubMed ID: 30689734
[TBL] [Abstract][Full Text] [Related]
19. Differential role of dopamine in emotional attention and memory: evidence from Parkinson's disease.
Hälbig TD; Assuras S; Creighton J; Borod JC; Tse W; Frisina PG; Voustianiouk A; Gracies JM; Olanow CW
Mov Disord; 2011 Aug; 26(9):1677-83. PubMed ID: 21638322
[TBL] [Abstract][Full Text] [Related]
20. Cognitive and motor effects of dopaminergic medication withdrawal in Parkinson's disease.
Fern-Pollak L; Whone AL; Brooks DJ; Mehta MA
Neuropsychologia; 2004; 42(14):1917-26. PubMed ID: 15381022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
